Skip to main content

Table 2 Treatment outcomes by test classification for the overall population (A), BRAF WT and BRAF MUT subgroups (B, C); and NLR < 5 and NLR ≥ 5 subgroups (D, E)

From: Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Classification PFS OS
BDX008- BDX008+ BDX008- BDX008+
A: All patients (N = 71)
 2 years PFS or OS 17% 20% 22% 43%
 Median, months (95% CI) 2.8 (2.1–3.2) 10.8 (5.1–19.7) 4.9 (2.9–9.8) 18.3 (12.6–41.4)
 HR – vs + (95% CI) 0.61 (0.37–1.02) 0.50 (0.29–0.88)
 P value 0.060 0.016
B: BRAF WT, excluding uveal (N = 36)
 2 years PFS or OS 24% 20% 24% 53%
 Median, months (95% CI) 3.0 (2.1–9.99) 18.7 (5.1–22.7) 6.0 (3.1–18.0) 32.5 (12.6-Undf*)
 HR – vs + (95% CI) 0.70 (0.35–1.42) 0.41 (0.18–0.93)
P value 0.321 0.032
C: BRAF MUT (N = 25)
 2 years PFS or OS 8% 25% 23% 33%
 Median, months (95% CI) 2.2 (0.99–3.4) 4.5 (0.99-Undf) 2.9 (2.1–11.2) 12.3 (1.25-Undf)
 HR – vs + (95% CI) 0.55 (0.23–1.36) 0.73 (0.29–1.80)
P value 0.196 0.489
D: NLR < 5 (N = 44)
 2 years PFS or OS 21% 20% 21% 52%
 Median, months (95% CI) 2.9 (2.2–10.0) 13.2 (6.2–22.7) 6.8 (2.9–15.7) 29.7 (15.2-Undf)
 HR – vs + (95% CI) 0.63 (0.33–1.22) 0.38 (0.19–0.79)
P value 0.169 0.008
E: NLR ≥5 (N = 27)
 2 years PFS or OS 14% 0% 23% 0%
 Median, months (95% CI) 2.4 (1.0–3.4) 1.1 (0.6–5.1) 3.8 (2.1–11.2) 1.8 (0.99–8.6)
 HR – vs + (95% CI) 1.88 (0.69–5.14) 1.80 (0.65–5.00)
P value 0.220 0.255
  1. *Undf = Undefined